Most if not all people here don't know this, but this is a huge deal. This is my 3rd time trying to post this, but I think I figured out why they keep taking it down because I posted a website maybe?? Last time trying. Anyway-Jeff Bluestone is the top type I diabetes researcher in the country. He is looking at taking cells called regulatory t cells, a controller of autoimmunity, from early diabetic patients (kids) and trying to see if he can expand and activate the cells to suppress their immune system. Also wants to do the same in patients at risk for diabetes to prevent the disease. Here's the skinny. Bluestone's lab(s) are a fine tuned machine. He has over 100 million in NIH grant money as he runs the UCSF translational science center. Not gonna post the website this time. But go to search browser and type "NIH Reporter" then Bluestone's name. His center has been likened to the NIH of the west, as his center can redistribute those funds to grant money to investigators with novel ideas. To my knowledge this is the highest funded center currently and the most money that the NIH gave to one center. For him to trust NBS with making the cells for his most important project is huge, and will give NBS a steady flow of large amounts of income. So suck it Anti-quated and stop posting. You make me tired with your garbage.
This thread is one I started back in July when I found out about the news from the collaboration with Jeff Bluestone. What Robin Smith said in her recent interview transcript with Wall Street Transcript completely reiterates my point above.
From the transcript of the interview with Robin Smith:
"Athelos is really exciting. This is not a stem cell therapy; it's actually a Treg therapy. When one's immune system becomes imbalanced, it can cause MS, lupus, steroid-resistant asthma, Type I diabetes. Athelos is a way of taking a person's T-cells and expanding their regulatory cells and giving it back to them in a way that should be able to put a person's immune system back into balance. We were able to fast-track the work that we had to do as a company through our partnership with UCSF and Jeffrey Bluestone, who is working on Type I diabetes in children. There has been some very exciting early results that should allow us to be able to go right into Phase II with him. We are pretty excited about our ability to go quicker into clinical trials, and we'll also be working on steroid-resistant asthma as well, since about half of the people now that have asthma become..."
NBS has secured a couple of revenue generating contracts this quarter. I am hoping that this reverse stock split was done now because a good earnings report is on the horizon. Increased share price + a good earnings report could help the share price quite a bit.
Your "semi-dissertation" is excellent, supports many of my same views, but also answers many questions.
Thank you for your time and effort.
I personally believe the CEO and staff have made excellent strides in promoting NBS at all the "key conferences" over the past several months. I believe the rs was executed at a time when fund managers studed the big picture (business plan) and will now gradually buy into NBS knowing that prior to the rs the stk was traded like any penny micro-stk.
The large blk buy ($73k++) at Fri close "may" be one indication of what might be considered confirmation of the business plan leading to bigger things. We shall see.
Let's see now... a group of people from Yale, Harvard & Stanford got together and decided "now" is the time to do a 10/1 reverse split because we think earnings are going to be a disappointment this quarter. Hmm.... I feel like an idiot XD.
Sentiment: Strong Buy
It is very frustrating to try and post articles anymore on Yahoo; so thanks very much for your extra effort. Additionally NBS has been given strong grants from DOD and other credible sources ever since I have been in the stock. There's certainly a message there somewhere!